Attenuation of ischemia/reperfusion injury
AssigneeMedical University of South Carolina
InventorInderjit Singh
Life of this patent
Estimating the term…
Abstract
This current invention includes compositions and methods of nitric oxide synthase inhibitors to treat or reduce ischemia/reperfusion injury in a patient. More specifically, the invention relates to a combinational therapy of 5-Aminoimidazole-4-carboxamide-1-B-D-ribonucleoside (AICAR) and N-acetyl cysteine (NAC) to attenuate ischemia/reperfusion injury to a transplanted organ.
Claims19
A method for reducing ischemic/reperfusion injury to an organ in a patient comprising administering a therapeutically effective amount of 5-aminoimmidazole-4-carboxamide ribonucleoside (AICAR) and N-acetyl cysteine (NAC) to the patient.
A method for reducing the risk of organ failure caused by ischemic/reperfusion injury in a patient comprising administering a therapeutically effective amount of 5-aminoimmidazole-4-carboxamide ribonucleoside (AICAR) and N-acetyl cysteine (NAC) to the patient.
A method of reducing delayed graft function of a transplanted organ in a patient comprising administering a therapeutically effective amount of 5-aminoimmidazole-4-carboxamide ribonucleoside (AICAR) and N-acetyl cysteine (NAC) to the patient.
A pharmaceutically acceptable composition comprising 5-aminoimmidazole-4-carboxamide ribonucleoside (AICAR) and N-acetyl cysteine (NAC).
Dependencies are inferred from the claim text.